Adalimumab for sight-threatening uveitis in Behçet's disease
- PMID: 16601736
- DOI: 10.1038/sj.eye.6702352
Adalimumab for sight-threatening uveitis in Behçet's disease
Abstract
Aims: To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy.
Methods: Case note review. Main outcome measure was recurrence of uveitis.
Results: All patients remained free of recurrence with stable visual acuities.
Conclusions: Adalimumab appears to maintain disease remission in Behçet's disease.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical